Edition:
India

Cardiome Pharma Corp (CRME.OQ)

CRME.OQ on NASDAQ Stock Exchange Capital Market

1.49USD
15 Dec 2017
Change (% chg)

$0.06 (+4.20%)
Prev Close
$1.43
Open
$1.43
Day's High
$1.50
Day's Low
$1.43
Volume
11,600
Avg. Vol
29,162
52-wk High
$4.83
52-wk Low
$1.29

Latest Key Developments (Source: Significant Developments)

Cardiome Announces Strategic Licensing Agreement To Commercialize Aggrastat In Russia
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Cardiome Pharma Corp ::CARDIOME ANNOUNCES STRATEGIC LICENSING AGREEMENT TO COMMERCIALIZE AGGRASTAT IN RUSSIA.CARDIOME PHARMA CORP - AFFILIATE CORREVIO HAS ENTERED INTO AN EXCLUSIVE LICENSE AND DISTRIBUTION AGREEMENT WITH ZAO FIRMA EUROSERVICE.CARDIOME PHARMA - AS PER LICENSE AGREEMENT, ZAO WILL BE RESPONSIBLE FOR OBTAINING REGULATORY APPROVALS FOR AGGRASTAT FROM RUSSIA'S MINISTRY OF HEALTH.CARDIOME PHARMA CORP - ADDITIONAL TERMS OF AGREEMENT WERE NOT DISCLOSED.  Full Article

Cardiome Q3 loss per share $0.20
Wednesday, 15 Nov 2017 

Nov 14 (Reuters) - Cardiome Pharma Corp :Cardiome reports third quarter 2017 financial results.Sees fy 2017 revenue $24 million to $26 million.Q3 revenue $6.0 million versus I/B/E/S view $7.3 million.Q3 loss per share $0.20.Q3 earnings per share view $-0.18 -- Thomson Reuters I/B/E/S.Cardiome Pharma Corp - expects existing cash and cash equivalents will be sufficient to fund its operations for at least next 12 months..  Full Article

Cardiome Pharma commercially launches Xydalba in Sweden, Finland and Republic Of Ireland​
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Cardiome Pharma Corp -:Cardiome Pharma - has initiated commercial launch of Xydalba (dalbavancin hydrochloride) in Sweden, Finland and Republic Of Ireland​.  Full Article

Cardiome Q2 loss per share $0.37
Wednesday, 10 Aug 2016 

Cardiome Pharma Corp : Q2 revenue $5.9 million versus i/b/e/s view $6.8 million . Q2 earnings per share view $-0.20 -- Thomson Reuters I/B/E/S . Cardiome reports second quarter 2016 financial results . Q2 loss per share $0.37 .Cardiome pharma corp says gross margin decreased to 71.4% and 76.1% for three and six months ended june 30, 2016, respectively.  Full Article

Cardiome prices offering of 10 mln shares at $3.00 per share
Tuesday, 26 Jul 2016 

Cardiome Pharma Corp : Says aggregate gross proceeds to company of us$30 million . Cardiome announces pricing of public offering of 10,000,000 common shares .Offering of 10 million common shares from treasury at a price to public of $3.00 per common share.  Full Article

Cardiome announces proposed public offering
Tuesday, 26 Jul 2016 

Cardiome Pharma Corp : Cardiome announces proposed public offering of common shares .Says intends to use net proceeds from offering for in-licensing of dalbavancin.  Full Article

Cardiome says Esmocard and Esmocard Lyo receive pricing approval, reimbursement in Italy
Thursday, 14 Jul 2016 

Cardiome Pharma Corp : Esmocard® and Esmocard Lyo® receive pricing approval and reimbursement in Italy .Pricing approval and national reimbursement for both Esmocard(®) and Esmocard Lyo(®) (esmolol hydrochloride) was recently provided in Italy.  Full Article

Cardiome Q1 loss per share $0.06
Friday, 13 May 2016 

Cardiome Pharma Corp : Anticipate our first commercial sales of XYDALBA this year and a larger commercial roll-out during 2017 . Cardiome reports first quarter 2016 financial results . Q1 loss per share $0.06 . Q1 revenue $7.1 million versus I/B/E/S view $6.3 million .Q1 earnings per share view $-0.21 -- Thomson Reuters I/B/E/S.  Full Article

Cardiome Pharma reports Q1 2016 financial results
Friday, 13 May 2016 

Cardiome Pharma Corp :Cardiome reports first quarter 2016 financial results.  Full Article

Cardiome and Allergan announce Xydalba licensing agreement in international markets
Friday, 6 May 2016 

Cardiome Pharma Corp:Additional terms of agreement were not disclosed.Cardiome and allergan announce xydalba(tm) (dalbavancin) licensing agreement in international markets.Expects to initiate commercial sales of xydalba™ in its territories as early as 2016.  Full Article